NASDAQ:CDXCChromadex Stock Price, Forecast & News

Chromadex's stock was trading at $3.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDXC stock has increased by 29.6% and is now trading at $4.77. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chromadex.

Chromadex is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Chromadex.

Chromadex Corp (NASDAQ:CDXC) issued its earnings results on Monday, May, 11th. The company reported ($0.10) EPS for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.01. The firm earned $14.35 million during the quarter, compared to the consensus estimate of $13.76 million. Chromadex had a negative net margin of 58.73% and a negative return on equity of 132.48%. View Chromadex's earnings history.

3 analysts have issued 12-month price objectives for Chromadex's shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Chromadex's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 25.8% from the stock's current price. View analysts' price targets for Chromadex.

News headlines about CDXC stock have trended somewhat positive on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chromadex earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutChromadex.

Chromadex saw a drop in short interest in May. As of May 15th, there was short interest totaling 2,850,000 shares, a drop of 17.9% from the April 30th total of 3,470,000 shares. Based on an average trading volume of 526,800 shares, the short-interest ratio is presently 5.4 days. Currently, 7.5% of the company's stock are short sold. View Chromadex's Current Options Chain.

Some companies that are related to Chromadex include Aphria (APHA), Canopy Rivers (RIV), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), True Drinks (TRUU), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO) and Beleave (BE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include Heron Therapeutics (HRTX), Tilray (TLRY), TransEnterix (TRXC), Athersys (ATHX), Glu Mobile (GLUU), Axsome Therapeutics (AXSM), CELYAD SA/ADR (CYAD), Mesoblast (MESO), Sorrento Therapeutics (SRNE) and FuelCell Energy (FCEL).

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

Chromadex's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.13%), Tieton Capital Management LLC (2.45%), State Street Corp (1.17%), Geode Capital Management LLC (0.98%), UBS Group AG (0.37%) and Sargent Investment Group LLC (0.16%). Company insiders that own Chromadex stock include Kevin M Farr, Robert N Fried and Stephen A Block. View institutional ownership trends for Chromadex.

CDXC stock was sold by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Morgan Stanley, UBS Group AG, Group One Trading L.P., Raymond James Financial Services Advisors Inc., and BlackRock Inc.. View insider buying and selling activity for Chromadex.

CDXC stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Sargent Investment Group LLC, State Street Corp, Alliancebernstein L.P., BNP Paribas Arbitrage SA, Wells Fargo & Company MN, and Citigroup Inc.. Company insiders that have bought Chromadex stock in the last two years include Kevin M Farr, and Robert N Fried. View insider buying and selling activity for Chromadex.

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDXC stock can currently be purchased for approximately $4.77.

Chromadex has a market capitalization of $293.25 million and generates $46.29 million in revenue each year. The company earns $-32,150,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chromadex employs 100 workers across the globe.

The official website for Chromadex is www.chromadex.com.

Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at investorrela[email protected]